留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

ABO血型不相容肝移植策略

张晓峰, 朱震宇. ABO血型不相容肝移植策略[J]. 器官移植, 2024, 15(1): 33-39. doi: 10.3969/j.issn.1674-7445.2023187
引用本文: 张晓峰, 朱震宇. ABO血型不相容肝移植策略[J]. 器官移植, 2024, 15(1): 33-39. doi: 10.3969/j.issn.1674-7445.2023187
Zhang Xiaofeng, Zhu Zhenyu. Strategies for ABO-incompatible liver transplantation[J]. ORGAN TRANSPLANTATION, 2024, 15(1): 33-39. doi: 10.3969/j.issn.1674-7445.2023187
Citation: Zhang Xiaofeng, Zhu Zhenyu. Strategies for ABO-incompatible liver transplantation[J]. ORGAN TRANSPLANTATION, 2024, 15(1): 33-39. doi: 10.3969/j.issn.1674-7445.2023187

ABO血型不相容肝移植策略

doi: 10.3969/j.issn.1674-7445.2023187
基金项目: 国家自然科学基金重大计划集成项目(92159305)
详细信息
    作者简介:
    通讯作者:

    朱震宇(ORCID 0000-0002-6926-5141),Email:zhuzy302@163.com

  • 中图分类号: R617, R329.2

Strategies for ABO-incompatible liver transplantation

More Information
  • 摘要: 随着器官移植的高速发展,全球性器官短缺问题日益凸显。肝移植是目前治疗终末期肝病最有效的手段,但供者短缺一直是制约肝移植发展的关键问题,我国是乙型病毒性肝炎大国,供肝短缺问题尤为显著,很多危重症患者往往因为无法及时获得匹配的供肝,而失去最佳时机甚至死亡。ABO血型不相容(ABOi)肝移植作为一种扩大供者资源的策略,为那些等待合适供者的患者提供了新的希望。然而,由于ABOi肝移植术后更容易发生严重感染、抗体介导的排斥反应(AMR)、胆道并发症、血栓性微血管病以及急性肾损伤等并发症,因此备受争议。本文综述了ABOi肝移植的术前、术中和术后策略研究进展,旨在为ABOi肝移植临床应用及研究提供参考。

     

  • [1] HILL AL, KHAN M, KIANI AZ, et al. Global liver transplantation: emerging trends and ethical challenges[J]. Langenbecks Arch Surg, 2023, 408(1): 418. DOI: 10.1007/s00423-023-03144-4.
    [2] 朱志军. ABO血型不相容肝移植的免疫抑制策略[J]. 中国普外基础与临床杂志, 2021, 28(8): 981-986.

    ZHU ZJ. Immunosuppressive strategies for ABO-incompatible liver transplantation[J]. Chin J Bases Clin Gen Surg, 2021, 28(8): 981-986.
    [3] 韩环立, 戴小科, 李英存,等. ABO血型不相容儿童活体肝移植临床分析[J]. 四川大学学报(医学版), 2022, 53(5): 777-781.

    HAN HL, DAI XK, LI YC, et al. Clinical analysis of ABO-incompatible living-donor liver transplantation in children[J]. J Sichuan Univ (Med Sci), 2022, 53(5): 777-781.
    [4] JADAUN SS, SAIGAL S, AGARWAL S, et al. Practice of ABO-incompatible living donor liver transplant in India: an initial experience based on a survey[J]. J Clin Exp Hepatol, 2023, 13(5): 927-929. DOI: 10.1016/j.jceh.2023.04.007.
    [5] XIAO M, WAN Z, LIN X, et al. ABO-incompatible liver transplantation under the desensitization protocol with rituximab: effect on biliary microbiota and metabolites[J]. J Clin Med, 2022, 12(1): 141. DOI: 10.3390/jcm12010141.
    [6] EGAWA H, OIKE F, BUHLER L, et al. Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation[J]. Transplantation, 2004, 77(3): 403-411. DOI: 10.1097/01.TP.0000110295.88926.5C.
    [7] HONG SK, LEE KW, KIM JY, et al. Factors associated with rituximab-mediated B cell depletion in ABO-incompatible adult living donor liver transplantation[J]. Korean J Transplant, 2023, 37(3): 170-178. DOI: 10.4285/kjt.23.0031.
    [8] GAN K, LI Z, BAO S, et al. Clinical outcomes after ABO-incompatible liver transplantation: a systematic review and meta-analysis[J]. Transpl Immunol, 2021, 69: 101476. DOI: 10.1016/j.trim.2021.101476.
    [9] CHENG CH, LEE CF, WANG YC, et al. ABO-incompatible liver transplantation: state of art and future perspectives[J]. Curr Pharm Des, 2020, 26(28): 3406-3417. DOI: 10.2174/1381612826666200506094539.
    [10] LEE J, KIM EJ, YANG SJ, et al. Impact of the baseline anti-A/B IgG titer on the clinical outcome in ABO-incompatible liver transplantation[J]. Transplantation, 2020, 104(S3): S526. DOI: 10.1097/01.tp.0000701344.29242.43.
    [11] SASAKI K, KOBAYASHI S, IWAGAMI Y, et al. Rituximab administration one week before ABO-incompatible liver transplantation due to drug-induced acute liver failure with hepatic coma: a case report[J]. Clin J Gastroenterol, 2023, 16(5): 709-714. DOI: 10.1007/s12328-023-01827-5.
    [12] HIRUKAWA K, SHINODA M, HASEGAWA Y, et al. Long-term outcomes following ABO-incompatible living donor liver transplantation for acute liver failure: a single-center experience of over 20 years[J]. Surg Today, 2023, 53(10): 1160-1172. DOI: 10.1007/s00595-023-02678-w.
    [13] KIM JM, KWON CH, JOH JW, et al. ABO-incompatible living donor liver transplantation is suitable in patients without ABO-matched donor[J]. J Hepatol, 2013, 59(6): 1215-1222. DOI: 10.1016/j.jhep.2013.07.035.
    [14] MAKROO RN, AGRAWAL S, CHOWDHRY M, et al. Efficacy of single, extended and goal directed immunoadsorption in ABO incompatible living related donor liver transplantation[J]. Transfus Apher Sci, 2016, 55(3): 329-332. DOI: 10.1016/j.transci.2016.08.007.
    [15] USUI M, ISAJI S, MIZUNO S, et al. Experiences and problems pre-operative anti-CD20 monoclonal antibody infusion therapy with splenectomy and plasma exchange for ABO-incompatible living-donor liver transplantation[J]. Clin Transplant, 2007, 21(1): 24-31. DOI: 10.1111/j.1399-0012.2006.00572.x.
    [16] MONTEIRO I, MCLOUGHLIN LM, FISHER A, et al. Rituximab with plasmapheresis and splenectomy in ABO-incompatible liver transplantation[J]. Transplantation, 2003, 76(11): 1648-1649. DOI: 10.1097/01.TP.0000082723.02477.87.
    [17] EGAWA H, UMESHITA K, UEMOTO S. Optimal dosage regimen for rituximab in ABO-incompatible living donor liver transplantation[J]. J Hepatobiliary Pancreat Sci, 2017, 24(2): 89-94. DOI: 10.1002/jhbp.419.
    [18] EGAWA H. Challenge to ABO blood type barrier in living donor liver transplantation[J]. Hepatobiliary Pancreat Dis Int, 2020, 19(4): 342-348. DOI: 10.1016/j.hbpd.2020.06.017.
    [19] JADAUN SS, AGARWAL S, GUPTA S, et al. Strategies for ABO incompatible liver transplantation[J]. J Clin Exp Hepatol, 2023, 13(4): 698-706. DOI: 10.1016/j.jceh.2022.12.008.
    [20] IKEGAMI T, TAKETOMI A, SOEJIMA Y, et al. Rituximab, IVIG, and plasma exchange without graft local infusion treatment: a new protocol in ABO incompatible living donor liver transplantation[J]. Transplantation, 2009, 88(3): 303-307. DOI: 10.1097/TP.0b013e3181adcae6.
    [21] KIM SH, LEE EC, SHIM JR, et al. A simplified protocol using rituximab and immunoglobulin for ABO-incompatible low-titre living donor liver transplantation[J]. Liver Int, 2018, 38(5): 932-939. DOI: 10.1111/liv.13614.
    [22] JOHN GT, JACOB CK, SUNDARAM M, et al. The first ABO incompatible kidney transplantation without splenectomy in India - a review at 12 years[J]. Indian J Nephrol, 2023, 33(3): 234-236. DOI: 10.4103/ijn.ijn_295_21.
    [23] TANABE M, KAWACHI S, OBARA H, et al. Current progress in ABO-incompatible liver transplantation[J]. Eur J Clin Invest, 2010, 40(10): 943-949. DOI: 10.1111/j.1365-2362.2010.02339.x.
    [24] RAUT V, UEMOTO S. Management of ABO-incompatible living-donor liver transplantation: past and present trends[J]. Surg Today, 2011, 41(3): 317-322. DOI: 10.1007/s00595-010-4437-3.
    [25] OH J, KIM JM. Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation[J]. Clin Mol Hepatol, 2020, 26(1): 1-6. DOI: 10.3350/cmh.2019.0023.
    [26] EGAWA H, OHDAN H, SAITO K. Current status of ABO-incompatible liver transplantation[J]. Transplantation, 2023, 107(2): 313-325. DOI: 10.1097/TP.0000000000004250.
    [27] 曲伟, 朱志军, 魏林,等. Rituximab+IVIG方案预防儿童ABO血型不相容肝移植血型抗体介导排斥反应效果的临床研究[J]. 中国普外基础与临床杂志, 2021, 28(8): 987-991.

    QU W, ZHU ZJ, WEI L , et al. Clinical research of effect of rituximab +IVIG regimen to prevent pediatric ABO incompatible living donor liver transplantation[J]. Clin J Bases Clin Gen Surg, 2021, 28(8): 987-991.
    [28] MOON DB, LEE SG, KANG WH, et al. Adult living donor liver transplantation for acute-on-chronic liver failure in high-model for end-stage liver disease score patients[J]. Am J Transplant, 2017, 17(7): 1833-1842. DOI: 10.1111/ajt.14198.
    [29] SKOGSBERG DAHLGREN U, HERLENIUS G, GUSTAFSSON B, et al. Excellent outcome following emergency deceased donor ABO-incompatible liver transplantation using rituximab and antigen specific immunoadsorption[J]. Scand J Gastroenterol, 2022, 57(1): 50-59. DOI: 10.1080/00365521.2021.1976269.
    [30] LEE WC, CHENG CH, LEE CF, et al. Quick preparation of ABO-incompatible living donor liver transplantation for acute liver failure[J]. Clin Transplant, 2022, 36(3): e14555. DOI: 10.1111/ctr.14555.
    [31] MYSORE KR, HIMES RW, RANA A, et al. ABO-incompatible deceased donor pediatric liver transplantation: novel titer-based management protocol and outcomes[J]. Pediatr Transplant, 2018, 22(7): e13263. DOI: 10.1111/petr.13263.
    [32] LEMOINE CP, BRANDT KA, KESWANI M, et al. Outcomes after ABO incompatible pediatric liver transplantation are comparable to ABO identical/compatible transplant[J]. Front Pediatr, 2023, 11: 1092412. DOI: 10.3389/fped.2023.1092412.
    [33] LEE TB, KO HJ, SHIM JR, et al. ABO-incompatible living donor liver transplantation with a simplified desensitization and immunosuppression protocol: a single-center retrospective study[J]. Exp Clin Transplant, 2021, 19(7): 676-685. DOI: 10.6002/ect.2021.0025.
    [34] PERRY DK, BURNS JM, POLLINGER HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production[J]. Am J Transplant, 2009, 9(1): 201-209. DOI: 10.1111/j.1600-6143.2008.02461.x.
    [35] TAJIMA T, HATA K, OKAJIMA H, et al. Bortezomib against refractory antibody-mediated rejection after ABO-incompatible living-donor liver transplantation: dramatic effect in acute-phase?[J]. Transplant Direct, 2019, 5(10): e491. DOI: 10.1097/TXD.0000000000000932.
    [36] LEE WC, LEE CF, WU TH, et al. Clinical relevance of isoagglutinin rebound in adult ABO-incompatible living donor liver transplantation[J]. J Pers Med, 2021, 11(12): 1300. DOI: 10.3390/jpm11121300.
    [37] YANAGI Y, SAKAMOTO S, YAMADA M, et al. Acute antibody-mediated rejection coexisting with T cell-mediated rejection in pediatric ABO-incompatible transplantation[J]. Transplant Direct, 2022, 8(9): e1359. DOI: 10.1097/TXD.0000000000001359.
    [38] HAN CZ, WEI Q, YANG MF, et al. The critical role of therapeutic plasma exchange in ABO-incompatible liver transplantation[J]. Hepatobiliary Pancreat Dis Int, 2022, 21(6): 538-542. DOI: 10.1016/j.hbpd.2022.06.019.
  • 加载中
图(1)
计量
  • 文章访问数:  149
  • HTML全文浏览量:  111
  • PDF下载量:  28
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-09-25
  • 录用日期:  2023-11-22
  • 网络出版日期:  2023-11-29
  • 刊出日期:  2024-01-11

目录

    /

    返回文章
    返回